+130.43% Upside Potential. We may contact a candidate via text to schedule an interview; however, that text will always be accompanied by a corresponding email from our Company's domains ( example@ascendispharma.com ). 05/28 13:00. ET on SmarterAnalyst Analysts Say These 3 … Ascendis Pharma A/S (ASND) Q1 2021 Earnings Call Transcript. ASND earnings call for the period ending December 31, 2020. (S (A71.SG) stock analyst estimates, including earnings and revenue, EPS, upgrades and downgrades. Ascendis Pharma price target raised to $50 from $30 at Credit Suisse. June 11, 2021. Imagine an environment where success is not just a hopeful possibility, but a sustained inevitability because everything that surrounds you is geared toward achieving world-class performance. Global Drug Delivery Market Forecasts to 2024 - Anticipated to Exceed $1 Trillion by 2024, with Pfizer, Insulet Corp, West Pharmaceutical Services, Enable Injections and Ascendis Pharma … Royalty Pharma is followed by the analysts listed above as of March 2021. Ascendis Pharma is applying its innovative TransCon technologies to build a leading, fully integrated biopharmaceutical company focused on making a meaningful difference in patients’ lives. Analyst Coverage. View ASND financial statements in full. Marketing applications have been submitted in the United States and Europe for pediatric growth hormone deficiency (GHD). Ascendis Pharma A. The group has a global divisional operating model comprising of Pharma, Consumer Heathcare, Medical and Animal Health. MT Newswires. Learn More. Please note that any opinions, estimates or forecasts regarding Antares Pharma, Inc.'s performance made by these analysts are theirs alone and do not represent opinions, forecasts or predictions of Antares Pharma… Each ADS will represent one issued ordinary share. Ascendis Pharma will never ask for money as part of our recruitment process and will never make a job offer without a formal interview. The current price of the firm is $140.35. A high-level overview of Ascendis Pharma A/S (ASND) stock. MabVax Therapeutics (OTCMKTS:MBVXQ) and Ascendis Pharma A/S (NASDAQ:ASND) are both medical companies, but which is the better stock? Stifel Nicolaus initiated coverage on Ascendis Pharma A/S in a research report on Thursday, March 11th. Motley Fool Transcribers. We are offering $500,000,000 of American Depositary Shares, or ADSs, representing ordinary shares of Ascendis Pharma A/S. We are a dynamic workplace for employees to grow and develop their skills. We are passionate about patients and science, and we work together to achieve our vision and goals. As a member of our global team, you will influence the direction of the company and help us create new therapies to improve patients’ lives. This opens in a new window. Credit Suisse analyst Alethia Young said she now believes Ascendis Pharma's (ASND) TransCon hGH can have dominant market share if its Phase 3 trial succeeds after Versartis' (VSAR) non-inferiority study testing somavaratan failed. 06/01 08:49. Achondroplasia Market Latest Trends and Forecast Analysis 2027 | Ascendis Pharma A/S, BioMarin, Ribomic, QED Therapeutics Posted by Harshad Borde March 1, 2021 Posted in Industry Insights To understand the market in depth, Achondroplasia Market research report is … Stifel Nicolaus initiated coverage on Ascendis Pharma A/S in a research report on Thursday, March 11th. Antares Pharma, Inc. is followed by the analysts listed above. Associate salaries at Ascendis Pharma can range from $147,432-$158,529. Bottom Line Hey, guys, good afternoon. After the downgrade, the consensus from Ascendis Pharma's twelve analysts is for revenues of €8.5m in 2020, which would reflect a concerning 37% decline in … The plan is to randomise 57 subjects to the middle phase II dose of Transcon PTH (18µg/day), and 19 to placebo. Debt to Equity is calculated by dividing the Total Debt of ASCENDIS PHADRN by its Equity. then the creditors have more stakes in a firm than the stockholders. 2017 Avior investor lunch, Johannesburg 4.12.2017 Investor Remedica site visit 13/14th of November 2017 ASC Annual Results 2017 Presentation - RMB Off Piste Conference Sep17 Group Annual Results for year ended 30 June 2017 - Analyst Presentation Pre closing investor lunch Investec 12.6.2017 and Merrill Lynch 13.6.2017 Ascendis Health Interim Results 2017 - Analyst presentation … ... Do you expect to go for broad coverage with a wide array of payers or do you expect to be more selective in … (MFTranscribers) Mar 11, 2021 at 5:30AM. A 'game over' for Versartis' somavaratan; A powerful boost for Ascendis' TC-hGH. A research report on Friday, 28th August said that the Credit Suisse Group raised the price target on Ascendis Pharma A/S (NASDAQ:ASND) from $154.00 to $158.00. 5/31/2019 – Ascendis Pharma A/S had its price target raised by […] Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Medtronic (MDT – Research Report) and Ascendis Pharma (ASND – Research Report). Wedbush cut their price target on shares of Ascendis Pharma A/S from $219.00 to $189.00 and set an "outperform" rating on the stock in a … 2020 – nu 1 år 4 måneder. Stifel Nicolaus initiated coverage on shares of Ascendis Pharma A/S in a report on Thursday, March 11th. 9 February 2017 Ascendis Pharma A/S (ASND)3 Executive Summary We Are Initiating Coverage of Ascendis Pharma with an Outperform Rating and a $28 Target Price. 's earnings in 2021 is -$510,280,487.. On average, 7 Wall Street analysts forecast ASND's earnings for 2021 to be $-494,691,993, with the lowest ASND earnings forecast at $-569,514,830, and the highest ASND earnings forecast at $-290,678,647. Kit Zacho. Contact Information. Ascendis Pharma A/S ADR analyst ratings, historical stock prices, earnings estimates & actuals. Stifel Nicolaus assumed coverage on shares of Ascendis Pharma A/S in a report on Thursday, March 11th. ASCENDIS PHARMA A/S analysts consensus, targets, ratings and recommendations | Nasdaq: ASND | Nasdaq Brokerages predict that Ascendis Pharma A/S (NASDAQ:ASND) will report $660,000.00 in sales for the current fiscal quarter, Zacks reports. Analysts Offer Insights on Healthcare Companies: Ascendis Pharma (ASND) and Merck & Company (MRK) Apr. Ascendis Pharma A/S ... Analyst. They set a "buy" rating on the stock. Analyst Ratings For Ascendis Pharma A/S (NASDAQ:ASND) Today, Canaccord Genuity raised its price target on Ascendis Pharma A/S (NASDAQ:ASND) to $133.00 per share. Jesper Høiland has served as a member of our Board of Directors since April 2019. An ‘overweight’ rating was issued by JP Morgan. Ascendis Health Ltd is a drug manufacturer that produces and distributes health products for the human, animal, and plant markets. Ascendis Pharma A/S ADR analyst estimates, including ASND earnings per share estimates and analyst recommendations. Rate It! In a report issued on March 11, Stifel Nicolaus also initiated coverage with a Buy rating on the stock with a $190.00 price target. The analysts are definitely expecting Ascendis Pharma's growth to accelerate, with the forecast 5x growth ranking favourably alongside historical growth of 21% per annum over the past five years. MT Newswires. Ascendis Pharma is a well known stock, with plenty of analyst coverage, suggesting some visibility into future growth. Since May 2020, Mr. Høiland has served as Senior Vice President and Global Chief Commercial Officer at Ascendis Pharma A/S. Medtronic (MDT) Leerink Partners analyst Danielle Antalffy maintained a Hold rating on Medtronic today and set a price target of $138.00. Ascendis Pharma A/S (ASND Quick Quote ASND - Free Report) announced that the FDA has extended the review period of its biologics license … Below is a list of individual analysts that we are aware of that currently follow Fusion Pharmaceuticals.. The average price target is $53.67, with a high forecast of $66.00 and a low forecast of $35.00. 2017 Avior investor lunch, Johannesburg 4.12.2017 Investor Remedica site visit 13/14th of November 2017 ASC Annual Results 2017 Presentation - RMB Off Piste Conference Sep17 Group Annual Results for year ended 30 June 2017 - Analyst Presentation Pre closing investor lunch Investec 12.6.2017 and Merrill Lynch 13.6.2017 Ascendis Health Interim Results 2017 - Analyst presentation … Antares Pharma, Inc. is followed by the analysts listed above. Analyst Ratings For Ascendis Pharma A/S (NASDAQ:ASND) Today, Evercore ISI initiated coverage on Ascendis Pharma A/S (NASDAQ:ASND) with a Outperform . Analyst Coverage. Three analysts have issued estimates for Ascendis Pharma A/S’s earnings, with estimates ranging from $20,000.00 to $1.74 million. Ascendis Pharma A/S posted sales of $2.45 million in the same quarter […] 15, 2021 at 8:35 a.m. The lowest sales estimate is $600,000.00 and the highest is $3.57 million. Review. Analyst Coverage. It's nice to see that Ascendis Pharma shareholders have gained 89% (in total) over the last year. A research report on 14th September, Monday said that JPMorgan Chase & Co. assumed coverage on the company’s shares. Data is currently not available. Globally nearly 200,000 people suffer from hypoparathyroidism mainly due to accidental removal of parathyroid gland during thyroid surgery. Ascendis Pharma A/S ADR ASND ... are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst … Ascendis Pharma is looking to hire an experienced Vice President, Investor Relations to join our team. Please note that any opinions, estimates or forecasts regarding Antares Pharma, Inc.'s performance made by these analysts are theirs alone and do not represent opinions, forecasts or predictions of Antares Pharma… Ascendis Pharma … Shares of Ascendis Pharma A/S (NASDAQ:ASND) have earned a consensus recommendation of “Buy” from the eleven research firms that are presently covering the company, MarketBeat Ratings reports. Image source: The Motley Fool. Valuation & Earnings. Analyst Ratings are available for US and Canadian equities. Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and investment tools. Ascendis Pharma A/S (NASDAQ: ASND) stock closed at 130.36 per share at the end of the most recent trading day (a -0.35 % change compared to the prior day closing price) with a volume of 90.62K shares and market capitalization of 7.01B.Is a component of indices and it is traded on NASDAQ exchange. They issued a “buy” rating on the stock. ASND: Get the latest Ascendis Pharma (spons. A Different Perspective. Unlike Barchart Opinions (which calculate the Buy/Sell rating using a variety of short-medium and long-term technical indicators), the Analyst Ratings are more of a short-term indicator that gives you a feel for how outside industry experts are weighing in on a stock. Ascendis Pharma A/S (NASDAQ: ASND) stock closed at 134.5 per share at the end of the most recent trading day (a 2.24 % change compared to the prior day closing price) with a volume of 132.34K shares and market capitalization of 7.24B.Is a component of indices and it is traded on NASDAQ exchange. Hellerup, Capital Region, Denmark ... Vice President, CMC Development - Drug Substance & Analysis at Ascendis Pharma A/S København. The company’s shares closed last Friday at $127.24, close to its 52 … Analyst Coverage. The Company utilizes … One analyst has rated the stock with a sell rating, one has given a hold rating and nine have assigned a buy rating to the company. Analysts have been steadily raising their estimates for Ascendis Pharma A/S. They now have an “outperform” rating on the stock. Taking into account the latest results, the eleven analysts covering Ascendis Pharma provided consensus estimates of €18.5m revenue in 2020, which would reflect a … Yahoo. The list above may change as firms initiate or discontinue coverage. Summary Today we look at Ascendis Pharma, a company based outside the United States which does not get a whole lot of analyst coverage despite an over $5 billion market capitalization. So we recommend checking out this free report showing consensus forecasts. Ascendis Pharma A/S (NASDAQ:ASND) last posted its quarterly earnings data on Wednesday, May 26th. The company’s product pipeline consist of TransCon Human Growth Hormone, TransCon Treprostinil, TransCon Insulin, TransCon Peptide … See all Associate salaries to learn how this stacks up in … Analyst Ratings are available for US and Canadian equities. ADRs stock price and detailed information including ASND news, historical charts and realtime prices. ASCENDIS PHARMA A/S is a Danish-based biopharmaceutical company, which is involved in manufacture products for rare diseases. Last week saw the newest third-quarter earnings release from Ascendis Pharma A/S (NASDAQ:ASND), an important milestone in the company's journey to build a stronger business.Revenues of €2.2m crushed expectations, although expenses also blew out, with the company reporting a loss per share of €0.53, 57% bigger than analysts expected. The Optionality Value of the Emerging Pro-Drug Platform Is High: Ascendis is a pro-drug platform company that focuses on rare diseases related to endocrinology (hormones). 5 analysts offering 12-month price targets in the last 3 months for Ascendis Pharma evaluate the company at an average price target of $188.2 with a high of $201.00 and a … --Morgan Stanley Adjusts Price Target on Ascendis Pharma to $201 From $199, Maintains Overweight Rating. This price target is based on … The company belongs in the Biotechnology industry, Healthcare sector and employs 330 people. See Ascendis Pharma A/S Nav.-Akt. Ascendis Pharma A/S has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock. Three analysts have made estimates for Ascendis Pharma A/S’s earnings. SVB Leerink reduced their price target on Ascendis Pharma A/S from $191.00 to $181.00 and set an "outperform" rating for the company in a report on Monday. Ascendis Pharma recent selloff a buying opportunity, says Canaccord 07/08/21-9:25AM EST Thefly.com Argus Research Initiates Equity Report Coverage on Ascendant Resources Inc. (TSX: ASND) 06/01 11:17. Information Technology Business Analyst Ascendis Pharma A/S mar. 5 analysts offering 12-month price targets in the last 3 months for Ascendis Pharma evaluate the company at an average price target of $188.2 with a high of $201.00 and a … Unlike Barchart Opinions (which calculate the Buy/Sell rating using a variety of short-medium and long-term technical indicators), the Analyst Ratings are more of a short-term indicator that gives you a feel for how outside industry experts are weighing in on a stock. Ascendis Health employees possess three core competencies: their dedication to succeed, entrepreneurial spirit and most importantly integrity. SVB Leerink reduced their price target on Ascendis Pharma A/S from $191.00 to $181.00 and set an "outperform" rating for the company in a report on Monday. According to Zacks, “Ascendis Pharma A/S is a biopharmaceutical company. ASCENDIS PHADRN Debt to Equity is currently at 0.00%. Kit Zacho Group Compliance Manager at Ascendis Pharma A/S København. $133.84. Add to … Ascendis Health Limited is a health and wellness company listed in the healthcare sector of the JSE. Over the past three months, the Zacks Consensus Estimate for the company has increased 2.6%. +51.90% Upside Potential. By contrast, our data suggests that other companies (with analyst coverage) in a similar industry are forecast to grow their revenue at 21% per year. Our investigational growth hormone prodrug releases somatropin (rhGH or hGH) with once-weekly administration. Analyst Price Target is.

Revolut Customer Service Reddit, Holden Mckee Grey's Anatomy Actor, Closed-ended Questions, The Librarian: Quest For The Spear Full Movie Online, Guildford Demographics 2019, Angelo Fortunato Symbiote,